Summit Therapeutics (NASDAQ:SMMT) traded higher for the fifth straight session on Thursday as investors continued to cheer ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

Shares of Summit Therapeutics (NASDAQ:SMMT) ended five straight sessions of gains on Friday as the stock lost ~35%, ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

The collaboration reflects Ebn Sina Medical’s commitment to delivering high-quality medicinal products to the local market, ...

Beigene has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Beigene’s peers have a beta of 3.84, meaning that their average stock price is 284% ...

Beigene (NASDAQ:ONC – Free Report) had its target price raised by JPMorgan Chase & Co. from $311.00 to $317.00 in a report published on Monday,Benzinga reports.JPMorgan Chase & Co. currently has ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of lung cancer.

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET. Summit ...

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

There are four emerging powerhouses in China biotech: Henlius, BeiGene, Innovent and ZaiLab. All were founded in the 2010s, ...

BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer ...